Long-term effects of rivastigmine in moderately severe Alzheimer's disease
- 1 May 2002
- journal article
- clinical trial
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 26 (4) , 705-712
- https://doi.org/10.1016/s0278-5846(01)00326-8
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A 5-month, randomized, placebo-controlled trial of galantamine in ADNeurology, 2000
- Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil ExperienceJournal of Geriatric Psychiatry and Neurology, 1999
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsawBMJ, 1999
- The Stages of Alzheimer’s Disease: A ReappraisalDementia and Geriatric Cognitive Disorders, 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's DiseaseJAMA, 1994
- A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deteriorationAmerican Journal of Psychiatry, 1994
- Cholinergic Drugs in Alzheimer's DiseaseNew England Journal of Medicine, 1986
- A new rating scale for Alzheimer's diseaseAmerican Journal of Psychiatry, 1984
- The Global Deterioration Scale for assessment of primary degenerative dementiaAmerican Journal of Psychiatry, 1982